Biotron Limited  

(Public, ASX:BIT)   Watch this stock  
Find more results for BIT
0.0000 (0.00%)
Oct 7 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range     -
52 week 0.04 - 0.18
Open     -
Vol / Avg. 0.00/626,962.00
Mkt cap 17.26M
P/E     -
Div/yield     -
EPS -0.01
Shares 296.40M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -32.36% -162.85%
Operating margin -34.01% -165.70%
EBITD margin - -164.68%
Return on average assets -27.82% -84.05%
Return on average equity -30.79% -98.45%
Employees 4 -
CDP Score - -


Suite 1.9, 56 Delhi Road
+61-2-98050488 (Phone)
+61-2-98050688 (Fax)

Website links


Biotron Limited is an Australia-based biotechnology company. The Company is engaged in the funding and management of intermediate, and applied technology research and development projects. It is in development and commercialization of small molecule antiviral therapeutics targeting Hepatitis C virus (HCV) and human immunodeficiency virus (HIV)-1. Biotron has a pipeline of clinical programs developing antiviral drugs. Biotron's lead drug, BIT225, is a viroporin inhibitor in clinical development for treatment of HCV and HIV, as well as the hard to treat HIV/HCV co-infected population. It has completed Phase Ib/IIa HIV trial and demonstrated that BIT225 targets HIV replication in monocyte cells in treated patients, reducing virus levels in these cells. Biotron has early-stage programs addressing other viral diseases, including dengue virus. It also has a research and development program for next generation viroporin inhibitors for its HIV/HCV programs.

Officers and directors

Michelle Miller Ph.D. Chief Executive Officer, Managing Director, Executive Director
Peter James Nightingale Company Secretary
Michael John Hoy Independent Non-Executive Chairman of the Board
Susan Margaret Pond Independent Non-Executive Director
Age: 1
Robert Bain Thomas Independent Non-Executive Director
Age: 70
Denis Newell Wade Independent Non-Executive Director
Age: 77